Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Other Non-Current Assets (2018 - 2025)

BioNexus Gene Lab's Other Non-Current Assets history spans 8 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 25.92% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, down 25.92%, while the annual FY2024 figure was $1.5 million, 54.91% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $1.5 million at BioNexus Gene Lab, up from $1.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.3 million in Q1 2024 and bottomed at $849744.0 in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $1.5 million (2025), against an average of $1.8 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 245.17% in 2021 before it plummeted 54.91% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.5 million in 2021, then dropped by 2.48% to $1.5 million in 2022, then skyrocketed by 119.33% to $3.3 million in 2023, then tumbled by 54.91% to $1.5 million in 2024, then grew by 3.16% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Other Non-Current Assets are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $2.5 million (Q1 2025).